Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Wednesday May 03, 2023
Wednesday May 03, 2023
touchCONGRESS for touchONCOLOGY
Listen to renowned experts in gynaecological oncology Dr Domenica Lorusso, Dr Susana Banerjee and Prof. Frederik Marmé review key data presented at SGO 2023 on recent developments in the use of PARP inhibitors in ovarian cancer. Aspects covered include first-line maintenance therapy, selection and sequencing implications, and future directions including emerging neoadjuvant and combination regimens. They also discuss how these latest data may impact clinical practice.
Clinical themes:
- Update on first-line PARP inhibitor maintenance in ovarian cancer: Where are we now? (02:31)
- Selection and sequencing implications for PARP inhibitors in ovarian cancer emerging from the latest data: What should we consider, and when? (19:51)
- Emerging PARP inhibitor-based neoadjuvant and combination regimens in ovarian cancer: Where are we heading? (40:10)
The internationally renowned expert faculty:
- Dr Domenica Lorusso, Fondazione Policlinico Universitario A Gemelli, Rome, Italy
- Dr Susana Banerjee, The Royal Marsden NHS Foundation Trust, London, UK
- Prof. Frederik Marmé, University Hospital Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs outside of the USA only.
This activity is funded by an independent medical education grant from GlaxoSmithKline, and is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/congress-sgo-2023-updates-parp-inhibitors-ovarian-cancer/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.